Evidence map›Paper›PMID 38400862›Full record

ArticleJournal of cancer research and clinical oncology2024

A novel EIF3C-related CD8

Rui Li, Yikai Wang, Xin Wen, Binglin Cheng, Ruxue Lv, Ruzhen Chen, Wen Hu, Yinglei Wang, Jingwen Liu, Bingyi Lin and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Rui Li *Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.
Yikai Wang *Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.
Xin Wen *Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.
Binglin ChengDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.
Ruxue LvDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.
Ruzhen ChenDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.
Wen HuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.
Yinglei WangThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.
Jingwen LiuThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.
Bingyi LinThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.
Haixiang ZhangThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.
Enting ZhangThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong Province, China.
XinRan TangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China. tangxran@163.com.
Southern Medical University · CNSun Yat-sen University · CN

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2019A1515110076National Natural Science Foundation of China 81903134National Natural Science Foundation of China 82003214Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University 2018J005
6 · The paper itself

Abstract

purposeAt present, dysfunctional CD8

methodsUtilizing various algorithms for immune-infiltration evaluation, we explored the role of EIF3C in the TIME. We next found the influence of EIF3C expression on NPC based on functional analyses and RNA sequencing. By performing correlation and univariate Cox analyses of CD8

resultsOur results demonstrate a significant relationship between low expression of EIF3C and high levels of CD8

conclusionOur findings suggest that EIF3C plays a significant role in NPC progression and immune modulation, particularly in CD8

Indexed as

CD8-Positive T-LymphocytesNasopharyngeal NeoplasmsHumansImmunotherapyNasopharyngeal CarcinomaPrognosisTumor MicroenvironmentCD8+ T cellsEIF3CImmunotherapy responseNasopharyngeal carcinomaPrognosis

Identifiers

PMID38400862
PMCPMC10894114
OpenAlexW4392132285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.